As part of the French Project Call “Grand Défi Biomédicaments” CLIMBIN, a collaborative R&D project, obtained funding from BPI France to meet the societal challenge of producing new biotherapies and production tools.
CLIMBIN aims to develop an innovative process analytical control solution that addresses the issue of optimizing and automating cell culture systems, in USP (upstream process) and DSP (downstream process). This solution will allow CDMOs (Contract Development and Manufacturing Organization) to reduce their production times and costs and thus make therapeutic products accessible to the greatest number of patients.
This collaborative project is carried out by the NMNS laboratory -of the University of Tours, the LRGP laboratory of the University of Lorraine / CNRS, the Bio3 of the University of Tours (IMT Group), Ondalys, INDATECH – Chauvin Arnoux Group, and the Servier pharmaceutical group.
Dans le cadre de ce projet, il est prévu la création dune dizaine d’emplois en R&D, bureau d’étude et prestation de services.This project provides for the hiring of around ten people in R&D, design and services.
The development of biotherapies (recombinant proteins, antibodies, vaccines) and drugs for innovative therapy (drugs for gene therapy, drugs for somatic cell therapy, drugs from cell or tissue engineering, combined drugs for innovative therapy) is a real opportunity to better care for patients.